Efgartigimod PH20 SC Market Driven by Rising Adoption and Expanding Therapeutic Opportunities, 2026-2034
Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Efgartigimod PH20 SC Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report delivers a comprehensive assessment of the commercial outlook for efgartigimod PH20 SC, marketed as VYVGART HYTRULO, across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The analysis covers historical performance, current market dynamics, and sales forecasts from 2020 through 2034.
The report evaluates efgartigimod PH20 SC in approved indications, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), alongside potential indications such as bullous pemphigoid, Graves' ophthalmopathy, myositis, pemphigus, Sjogren's syndrome, lupus nephritis, and renal transplant rejection. It also examines regulatory milestones, clinical development, pricing, reimbursement, competitive positioning, patent considerations, and potential generic entry.
Key Factors Driving Efgartigimod PH20 SC Market Growth
Recent Efgartigimod PH20 SC Developments
In April 2026, argenx presented new VYVGART data in myasthenia gravis and CIDP at the American Academy of Neurology Annual Meeting in Chicago. The presentations included findings for intravenous VYVGART and subcutaneous VYVGART HYTRULO, as well as updates on adimanebart in congenital myasthenic syndromes and the company's broader neuromuscular pipeline. This pipeline includes Phase III studies evaluating empasiprubart in CIDP.
Efgartigimod PH20 SC Product Overview
VYVGART HYTRULO combines efgartigimod alfa with recombinant human hyaluronidase PH20 and is administered subcutaneously. Developed by argenx using hyaluronidase technology licensed from Halozyme Therapeutics, the therapy targets FcRn and reduces circulating immunoglobulin G, including pathogenic IgG autoantibodies.
Clinical studies in gMG and CIDP have reported reductions in IgG levels and improvements in relevant measures of muscle strength, disability, and quality of life, with a generally favorable safety profile. Reported adverse events include injection-site reactions, headache, respiratory tract infections, and urinary tract infections. The therapy received FDA approval for anti-acetylcholine receptor antibody-positive gMG in 2023 and for CIDP in 2024, becoming the first FcRn inhibitor approved for CIDP.
Scope of the Efgartigimod PH20 SC Market Report
Market and Competitive Analysis
The efgartigimod PH20 SC market forecast assesses projected revenue, peak sales potential, prescription growth, treatment duration, and uptake across approved and anticipated indications. It also evaluates the product's market positioning against established therapies and emerging competitors, including its clinical differentiation, administration profile, strengths, weaknesses, and potential commercial risks.
The competitive landscape is expected to evolve as additional FcRn inhibitors and other targeted autoimmune therapies reach the market. Late-stage products in gMG, CIDP, and potential expansion indications may influence pricing, reimbursement, market share, and treatment sequencing. However, VYVGART HYTRULO's early market entry, established clinical profile, expanding international presence, and self-administration option may support continued uptake.
Report Methodology
The analysis is based on internal databases, primary research, secondary research, and in-house review by industry experts. Sources include regulatory authorities, clinical trial registries, company disclosures, medical and trade journals, industry associations, white papers, news publications, and subscription databases. Findings are consolidated to provide an evidence-based view of the efgartigimod PH20 SC market, sales outlook, and competitive environment.
Key Report Highlights
The report addresses critical strategic questions concerning efgartigimod PH20 SC's clinical and commercial performance, forecast assumptions, regional sales potential, treatment costs, regulatory designations, competitive threats, development timelines, and opportunities across approved and potential indications. It is designed to support pharmaceutical companies, investors, healthcare consultants, market-access teams, and other stakeholders evaluating the future of VYVGART HYTRULO and the expanding FcRn inhibitor market.
For more information about this report visit https://www.researchandmarkets.com/r/gphi2x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.